Insmed Incorporated
INSM
Rang în acțiuni
#1107
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Preț acțiune
$95.65
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$20.89B
Schimbare (1 zi)
-0.65%
Schimbare (1 an)
-43.04%
Țară
US
Tranzacționează Insmed Incorporated (INSM)
Categorie
Healthcare
Raport P/S pentru Insmed Incorporated (INSM)
Raport P/S la data de October 2026 TTM: 18.77
Conform celor mai recente rapoarte financiare și prețului acțiunilor Insmed Incorporated, raportul P/S actual (TTM) este 18.77. La sfârșitul anului 2023, compania avea un P/S de 14.26.
Istoricul raportului P/S pentru Insmed Incorporated din 2000 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 18.77 | -39.72% |
| 2024 | 31.14 | 118.38% |
| 2023 | 14.26 | 42.32% |
| 2022 | 10.02 | -38.17% |
| 2021 | 16.20 | -18.01% |
| 2020 | 19.76 | 33.56% |
| 2019 | 14.80 | -85.57% |
| 2018 | 102.51 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | 57.87 | 11.92% |
| 2013 | 51.71 | 0.00% |
| 2012 | 0.00 | -100.00% |
| 2011 | 16.12 | 33.50% |
| 2010 | 12.08 | 27.98% |
| 2009 | 9.44 | 93.34% |
| 2008 | 4.88 | -61.16% |
| 2007 | 12.57 | -85.15% |
| 2006 | 84.64 | -88.45% |
| 2005 | 732.99 | 16.61% |
| 2004 | 628.56 | -10.83% |
| 2003 | 704.88 | 9,371.65% |
| 2002 | 7.44 | -98.25% |
| 2001 | 424.21 | -59.94% |
| 2000 | 1.06K | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.02 | -46.61% |
US
|
|
| 40.55 | 116.02% |
US
|
|
| 3.96 | -78.90% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -45.95% |
NL
|
